CalciMedica is trading 5.8% down at $1.05, a move consistent with broader market pressure after hotter-than-expected September inflation lifted Treasury yields and weighed on equities.
- No clear company-specific announcement explaining the decline was identified; CalciMedica’s press-release listing shows no October 14 release.
- Biotech shares were also weaker, with the XBI down 2.01% during the session.